Object We summarize 10 years of experience with liver transplantation for FAP patients in Japan and review the current opinions regarding this treatment for FAP.
Introduction
Familial amyloid polyneuropathy (FAP) is one type of hereditary generalized amyloidosis, initially showing polyneuropathy and autonomic dysfunction but with later involvement of many visceral organs (1) . Four endemic areas of this disease are known to exist in Portugal (2), Sweden (3), and Japan (1) . The precursor protein of amyloid fibrils is a variant form of transthyretin (TTR) in serum (4) . The vast majority of patients show the typical clinical picture known as type I FAP: the disease is caused by a mutation in the TTR gene resulting in the substitution of methionine for valine at position 30 (Val30Met) (5) . Polyneuropathy begins in the legs and progresses in an ascending fashion. As TTR is produced mainly in the liver, liver transplantation for FAP patients was first performed in 1990 in Sweden (6) , which was shown to result in the disappearance of variant TTR with Val30Met from the sera of transplant recipients. Since then, more than 800 patients in 16 countries have undergone orthotopic liver transplantation (OLT) (7) . Moreover, domino (sequential) liver transplantation using a graft from the FAP patient was first performed in Portugal (8) in 1995, and more than 200 domino transplant procedures reutilizing explanted FAP livers had been performed by the end of 2002 (7, 9) .
The first liver transplant in a Japanese FAP patient was carried out in November 1993 at Shinshu University Hospital (10, 11) , using living donor liver transplantation (LDLT). This transplantation method that includes domino liver transplantation has since been employed at different institutes in Japan. Here, we summarize 10 years of experience with liver transplantation for FAP patients in Japan and review the current opinions regarding this treatment for FAP.
Materials and Methods
All basic report data on patients at the time of transplantation were registered with the Japanese Liver Transplantation Society (JLTS). Centers report data on patients at the time of transplantation, operative procedures, including transplantation from living donor or cadaveric donor, and/or temporary auxiliary partial orthotopic liver transplantation (APOLT), and patient death. Based on the JLST report data, more detailed information on FAP patients was requested from each center: patients' weight, height, and serum albumin levels are necessary for calculation of the modified body mass index (mBMI). TTR gene mutation, neurological severity of FAP at transplantation, and pre-and postoperative states were also obtained. Furthermore, data regarding domino liver transplantation and Japanese FAP patients who underwent orthotopic liver transplantation (OLT) from a cadaveric donor overseas were collected.
Statistical analysis
Student's t-test was used to determine the significance of differences between normally distributed means. KaplanMeier estimation for actual patient survival curves was performed. All statistical analyses were two-sided and were conducted at the 0.05 significance level. Data are given as means±SD.
Results

Liver transplantation for FAP
By January 2004, a total of 43 patients had undergone liver transplantation in 9 centers in Japan ( Table 1 ). The patients consisted of 21 men and 22 women, ranging in age at liver transplantation from 26 to 63 years old (mean±SD, 40± 9 years old). Disease duration before liver transplantation ranged from 0.5 to 10 years (mean±SD, 3.2±2.0 years). Five different TTR gene mutations were reported (Table 2) . Among these, the Val30Met TTR mutation was the most common, including 36 cases. Seven had non-Val30Met TTR mutations: Tyr114Cys (n=3), Val30Leu (n=2), Ser50Ile (n=1), and Ser50Arg (n=1). Of the total of 43 patients, 41 had undergone LDLTs from living donors. Of these 41 LDLTs, APOLT was performed in 9 patients. Only 2 patients had undergone OLT from cadaveric donors.
Based on the neurological severity before transplantation, patients were staged clinically according to the criteria proposed by Coutinho et al (12) : some autonomic dysfunction was seen in 4 patients without any sensory or motor neuropathy (stage 0); twenty-six patients had polyneuropathy localized to the lower limbs (stage I); and neurological dysfunction was in the more advanced stages in the remaining 13 patients (stages II or III).
Among the total of 43 patients, 36 were alive, including one patient who showed graft failure after APOLT and was treated by removal of the transplanted graft 1 week later. Twenty-seven patients returned to their previous normal lives after transplantation, and 9 were in hospital or recuperated at home. Seven patients died after transplantation: with regard to the severity of FAP, three patients were in stage I and 4 were in stage II, and their causes of death were as follows: infection (n=2), hepatic artery thrombosis (n=2), multiple cerebral infarction (n=1), heart failure (n=1), and uterine carcinoma (n=1). The registry analysis during the follow-up of more than 1 year showed that mBMI of patients who returned to their normal lives were significantly higher than those of patients in hospital or recuperating at home (p<0.05) (Fig. 1) .
The one-year survival rate of all patients after transplantation was 93%, and their five-year survival rate was 77% (Fig. 2) . The one-year survival rate of patients after LDLT was 93%, and their five-year survival rate was 76%.
Living donors of LDLT
Among the 43 transplantations, 41 were LDLTs. All of the donors had undergone TTR gene diagnosis and were shown to be negative for TTR gene mutation. The age at operation ranged from 19 to 66 years old (mean±SD, 46±11), and they consisted of 25 men and 16 women. The intrafamilial relationships between living donors and FAP patients are shown in Table 3 . All of the living donors are alive and returned to their normal lives after the operation.
Domino liver transplantation
Twenty recipients underwent domino liver transplantation using the livers of FAP patients since 1999 in Japan. The age at transplantation ranged from 17 to 64 years old (mean±S D, 43±14 years old). The indications of domino recipients are shown in Table 4 . Among the 20 domino recipients, 12 were alive and 6 were dead, with no data available for the remaining 2.
Japanese FAP patients receiving OLT overseas
Twenty-one FAP patients with the Val30Met TTR mutation have undergone OLT from cadaveric donors (11 men and 10 women). Eight underwent OLT in Sweden, and 13 were treated in Australia. The ages at transplantation ranged from 28 to 49 years old (mean±SD, 36±6 years old). Disease duration before transplantation ranged from 1 to 6 years (mean±SD, 3.0±1.4). Among these 21 patients, only one died early after transplantation because of primary nonfunctional transplanted graft. The 20 surviving patients were all in good condition, and returned to their normal lives.
Discussion
Liver transplantation is now globally accepted for treatment of FAP patients. This therapy abolishes the hepatic source of amyloidogenic TTR variants in serum and progression of the disease has at least halted in the patients receiving The prognosis of FAP patients after liver transplantation seems to be dependent on their preoperative state (19) . FAPWTR emphasized that the severity of autonomic symptoms significantly affected the patient's recovery after operation, because many usually appeared in the patients at later stages of FAP (15) . However, gastrointestinal autonomic symptoms, including severe episodic nausea, vomiting, and alternating constipation and diarrhea, are often initial symptoms in Japanese patients with this disease (1), and these bowel dysfunctions improved shortly after transplantation in the FAP patients in our series (11, 18) . Therefore, FAP patients with only autonomic disturbances are considered good candidates for liver transplantation.
The mBMI is useful for estimating the nutritional status of patients. This index was reported to be correlated well with the prognosis of FAP patients after transplantation in foreign countries (20, 21) . The mBMI of patients who returned to their normal lives after liver transplantation in our country were significantly higher than those in hospital or recuperating at home at follow-up after more than one year. The mBMI of patients who died after transplantation tended to be lower than those in patients with good outcomes, except in one patient who died of endometrial carcinoma 4 years 11 months after transplantation. Our results regarding mBMI support those of previous reports (20, 21) , indicating that the nutritional state of FAP patients before transplantation is an important factor in predicting their post-operative state.
FAPWTR reported that the type of TTR gene mutation is a useful prognostic parameter (7, 15) . A better 5-year patient survival was reported in Val30Met TTR type FAP patients, as compared to those with non-Val30Met TTR type FAP (80% vs. 59%, respectively, p<0.001). In Japan, 2 patients with Val30Leu TTR type FAP underwent LDLT, but both died approximately one year after the operations. Autopsy revealed heavy deposition of amyloid on the myocardium in these two patients (22) . Serious cardiac involvement by amyloid is known to be one cardinal feature in FAP patients with non-Val30Met TTR type (16, 23) , and this severe phenotype of cardiac amyloidosis has been suggested to be responsible for the poor post-transplant prognosis in these FAP patients. Recently, it was noted that after transplantation rapid deterioration of cardiac function with further thickening of the ventricular wall occurred in some FAP patients, although polyneuropathy and autonomic dysfunction were stabilized or slightly improved. These findings were originally obtained in non-Val30Met TTR type patients who may have had substantial amyloid deposition on the myocardium prior to the operation (24) (25) (26) . However, a similar finding was reported in typical FAP patients with Val30Met TTR type (27) . Wild-type TTR is regarded as playing a central role in the pathogenesis of this form of cardiac amyloidosis (22) : wild-type TTR is inherently amyloidogenic, causing senile systemic amyloidosis (28) , and conversion of normal TTR to the amyloid fibril conformation may be promoted after liver transplantation using a preexisting template of variant TTR-derived amyloid deposits in the myocardium. Therefore, it is critical to clarify the severity of cardiac amyloid deposition when considering liver transplantation in FAP patients. To overcome this problem, combined heart and liver transplantation was carried out in a small number of FAP patients in other countries (29) .
As FAP patients who could obtain LDLT from a living donor in Japan were restricted, twenty-one FAP patients have undergone OLT in Australia or Sweden over the past 10 years (30) . Their preoperative conditions of FAP were not serious, which enabled them to go abroad, and the resultant post-operative outcomes were satisfactory.
Liver tissue explanted from FAP patients has normal structure and function except for the production of amyloidogenic variant TTR, and domino liver transplantation using FAP liver grafts has been employed to compensate for the shortage of available liver grafts (7) (8) (9) . In other countries, 70% of these operations were performed in patients with liver tumors, and 30% for non-malignant conditions (7) . In Japan, 20 domino recipients with different liver disorders underwent liver transplantation using grafts from FAP patients, and 65% of them suffered from non-malignant diseases. Development of FAP symptoms has not been reported in any of the domino recipients at up to 7 years follow-up worldwide. However, Sousa et al reported that fibrillar deposits of TTR were observed in the epineurium of the biopsied peripheral nerve in a domino recipient with a 6-year post-operative history (31) . Serial and careful follow-up of domino recipients is necessary.
In conclusion, LDLT from a living donor for the treatment of FAP is equally effective as OLT from a cadaveric donor and has changed the natural course of patients with this disease (32, 33) . Early intervention (less than 5 years after onset) can provide a better chance of improving patients' conditions after transplantation (34) . Considering that the graft size from a living donor is much smaller than that from a cadaveric donor, earlier transplantation is desirable. However, this treatment cannot prevent the production of variant TTR in the retina (35) or choroid plexus (36) , and long-term follow-up FAP recipients should undergo detailed examinations of ocular and central nervous system manifestations.
